Moreover, anti-CSPG4 vaccination was again of interest when the mimotope technology emerged, indeed immunizations with CSPG4 mimotopes resulted in an inhibition of proliferation, migration and invasion of CSPG4-positive melanoma cells through the induction of a specific antibody response responsible for both immunological and non-immunological antitumor functions [107–109]. The gene discussed is CSPG4; the disease is melanoma.